Premium
Patients not patents: Drug research and development as a public enterprise
Author(s) -
Gøtzsche Peter C.
Publication year - 2018
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12875
Subject(s) - business , commission , drug development , drug , nonsteroidal , clinical trial , profit (economics) , medicine , public health , pharmacology , finance , economics , nursing , pathology , microeconomics
Our current system for researching, developing, approving, marketing and using drugs is financially and morally unsustainable. I propose an entirely new system where drug research and development will be a public enterprise, with no patents, and defined entirely by the public interest. Drug companies will have a limited role, selling services on a competitive basis to the publicly funded enterprise. This article is protected by copyright. All rights reserved.